Citation: Hong-Xia LI, Yu-Mei QIAN, Li-Sheng XU. Design, Synthesis and Anticancer Activity Evaluation of Novel Quinazoline Derivatives as EFGR Inhibitors[J]. Chinese Journal of Structural Chemistry, ;2021, 40(7): 933-941. doi: 10.14102/j.cnki.0254–5861.2011–3082 shu

Design, Synthesis and Anticancer Activity Evaluation of Novel Quinazoline Derivatives as EFGR Inhibitors

School of Life and Food Engineering, Suzhou University, Suzhou 234000, China

Corresponding author: Hong-Xia LI, szxy2016hx@163.com
Received Date: 28 December 2020
Accepted Date: 12 March 2021

Fund Project: the Suzhou University Natural Science Key Project 2017yzd11the Suzhou University Natural Science Key Project 2020ykf23the Suzhou University Natural Science Key Project 2020ykf24National Engineering Laboratory Open Fund Project NEL-SCRT 002Natural Science Foundation of An Hui Province 1908085MC100Natural Science Foundation of An Hui Province KJ2020A0729Natural Science Foundation of An Hui Province KJ2020A0737

Figures(2)

Malignant tumor is one of the major diseases that seriously threaten human health today. Compared with traditional chemotherapy, targeted drug therapy has become a new idea of tumor therapy. And EGFR (epidermal growth factor receptor) is highly expressed in many human tumor cell lines, which is a biomarker of tumor proliferation. In this paper, small molecule tyrosine kinase inhibitors with quinazoline structure aiming at EGFR were studied. A series of novel quinazoline derivatives (4a~4l) have been designed and synthesized from 4-hydroxyquinazoline as the parent core. Structures of target compounds were characterized by ¹H NMR and ¹³C NMR spectra. The in vitro anticancer activity of compounds 4a~4l was evaluated by MTT assay against Hela, MCF-7 and A549 tumor cell lines, and apoptosis-inducing capacity was investigated by Annexin-V/PI staining assay. The results showed that all compounds had good antitumor activity against the test tumor cell lines. Especially, compound 4a exhibited the best anticancer activity (IC₅₀ = 10.23 μM) against Hela cell lines, remarkable ability to induce apoptosis, and low toxicity, which identified 4a as a promising anticancer drug aiming at EFGR.
- hydroxyquinazoline,
- EFGR,
- antitumor activity,
- toxicity,
- apoptosis
1. [1]
  Wang, Y. C.; Long, J. B.; Gao, H.; Tang, Z. L. 2-Aminothiazole: a privileged scaffold for the discovery of anti-cancer agents. Eur. J. Med. Chem. 2020, 210, 112953–112967.
2. [2]
  Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Inter. J. Cancer. 2015, 136, E359–86. doi: 10.1002/ijc.29210
3. [3]
  Mahoney, K. M.; Rennert, P. D.; Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 2015, 14, 561–584. doi: 10.1038/nrd4591
4. [4]
  Michot, J. M.; Bigenwald, C.; Champiat, S.; Collins, M.; Carbonnel, F.; Postel-Vinay, S.; Berdelou, A.; Varga, A.; Bahleda, R.; Hollebecque, A.; Massard, C.; Fuerea, A.; Ribrag, V.; Gazzah, A.; Armand, J. P.; Amellal, N.; Angevin, E.; Noel, N.; Boutros, C.; Mateus, C.; Robert, C.; Soria, J. C.; Marabelle, A.; Lambotte, O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer. 2016, 54, 139–148. doi: 10.1016/j.ejca.2015.11.016
5. [5]
  Miller, K. D.; Siegel, R. L.; Lin, C. C.; Mariotto, A. B.; Kramer, J. L.; Rowland, J. H.; Stein, K. D.; Alteri, R.; Jemal, A. Cancer treatment and survivorship statistics. Cancer J. Clin. 2016, 66, 271–289. doi: 10.3322/caac.21349
6. [6]
  Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93, 52–79. doi: 10.1016/j.ejpb.2015.03.018
7. [7]
  Postow, M. A. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book. 2015, 35, 76–83.
8. [8]
  Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein. L.; Verweij, J.; Van, G. M.; van, O. A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 3, 205–216.
9. [9]
  Chen, Z.; Jiang, S.; Li, X.; Zhang, J.; Zhang, L. Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials. Ann. Palliat. Med. 2021, 10, 21037/apm-20-1621.
10. [10]
  Andrade, J. T.; Santos, F. R. S.; Lima, W. G.; Sousa, C. D. F.; Oliveira, L. S. F. M.; Rosy, I. M. A.; Ribeiro, R. I. M. A.; Gomes, A. J. P. S.; Araújo, M. G. F.; Villar, J. A. F. P.; Ferreira, J. M. S. Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents. J. Antibiot. 2018, 71, 702–712. doi: 10.1038/s41429-018-0048-9
11. [11]
  Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England J. Med. 2004, 350, 2129–2139. doi: 10.1056/NEJMoa040938
12. [12]
  Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500. doi: 10.1126/science.1099314
13. [13]
  Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; Santos, G. C.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer-molecular and clinical predictors of outcome. New England. J. Med. 2006, 353, 133–144.
14. [14]
  Zheng, Y. G.; Zhang, W. Q.; Meng, L.; Wu, X. Q.; Zhang, L.; An, L.; Li, C. L.; Gao, C. Y.; Xu, L.; Liu, Y. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H₂S) donors as potent EGFR inhibitors against L858R resistance mutation. Eur. J. Med. Chem. 2020, 202, 112522–112532. doi: 10.1016/j.ejmech.2020.112522
15. [15]
  Thorn, D. A.; An, X. F.; Zhang, Y.; Pigini, M.; Li, J. X. Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats. Brit. J. Pharmacol. 2012, 166, 1936–1945. doi: 10.1111/j.1476-5381.2012.01894.x
16. [16]
  Nasr, M. N.; Gineinah, M. M. Pyrido 2, 3-d pyrimidines and pyrimido 5΄4΄: 5, 6 pyrido 2, 3-d pyrimidines as new antiviral agents: synthesis and biological activity. Arch. Pharm. 2002, 335, 289–295. doi: 10.1002/1521-4184(200208)335:6<289::AID-ARDP289>3.0.CO;2-Z
17. [17]
  Chandrika, P. M.; Yakaiah, T.; Rao, A. R. R.; Narsaiah, B.; Reddy, N. C.; Sridhar, V.; Rao, J. V. Synthesis of novel 4, 6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines. Eur. J. Med. Chem. 2008, 43, 846–852. doi: 10.1016/j.ejmech.2007.06.010
18. [18]
  Azzoli, C. G.; Ng, T. Commentary: preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: a stich in time, or delay from stiches? J. Thorac. Cardiovasc Surg. 2021, 161, 444–446. doi: 10.1016/j.jtcvs.2020.04.028
19. [19]
  Sequist, L. V.; Waltman, B. A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A. B.; Fidias, P.; Bergethon, K.; Shaw, A. T.; Gettinger, S.; Cosper, A. K.; Akhavanfard, S.; Heist, R. S.; Temel, J.; Christensen, J. G.; Wain, J. C.; Lynch, T. J.; Vernovsky, K.; Mark, E. J.; Lanuti, M.; Iafrate, A. J.; Mino-Kenudson, M.; Engelman, J. A. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, 75ra26.
20. [20]
  Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702–4711. doi: 10.1038/onc.2008.109
21. [21]
  Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Red, B. M.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Dis. 2014, 4, 1046–1061. doi: 10.1158/2159-8290.CD-14-0337
22. [22]
  Miura, S.; Yamanaka, T.; Kato, T.; Ikeda, S.; Horinouchi, H.; Ichihara, E.; Kanazu, M.; Takiguchi, Y.; Tanaka, K.; Goto, Y.; Sata, M.; Hagiwara, K.; Okamoto, H.; Tanaka, H. Treatment rationale and design of a phase III study of afatinib or chemotherapy in patients with nonesmall-cell lung cancer harboring sensitizing uncommon epidermal growth factor receptor mutations. Clin. Lung Cancer. 2020, 21, E592–E596. doi: 10.1016/j.cllc.2020.05.011
23. [23]
  Liang, Q.; Wang, J.; Zhao, L.; Hou, J.; Hu, Y.; Shi, J. Recent advances of dual FGFR inhibitors as a novel therapy for cancer. Eur. J. Med. Chem. 2021, 214, 113205–113205. doi: 10.1016/j.ejmech.2021.113205
1. [1]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
2. [2]
  Jin Wang , Xiaoyan Pan , Junyu Zhang , Qingqing Zhang , Yanchen Li , Weiwei Guo , Jie Zhang . Active molecule-based theranostic agents for tumor vasculature normalization and antitumor efficacy. Chinese Chemical Letters, 2024, 35(8): 109187-. doi: 10.1016/j.cclet.2023.109187
3. [3]
  Zhaomin Tang , Qian He , Jianren Zhou , Shuang Yan , Li Jiang , Yudong Wang , Chenxing Yao , Huangzhao Wei , Keda Yang , Jiajia Wang . Active-transporting of charge-reversal Cu(Ⅱ)-doped mesoporous silica nanoagents for antitumor chemo/chemodynamic therapy. Chinese Chemical Letters, 2024, 35(7): 109742-. doi: 10.1016/j.cclet.2024.109742
4. [4]
  Guangyao Wang , Zhitong Xu , Ye Qi , Yueguang Fang , Guiling Ning , Junwei Ye . Electrospun nanofibrous membranes with antimicrobial activity for air filtration. Chinese Chemical Letters, 2024, 35(10): 109503-. doi: 10.1016/j.cclet.2024.109503
5. [5]
  Ting Wang , Xin Yu , Yaqiang Xie . Unlocking stability: Preserving activity of biomimetic catalysts with covalent organic framework cladding. Chinese Chemical Letters, 2024, 35(6): 109320-. doi: 10.1016/j.cclet.2023.109320
6. [6]
  Xiangyuan Zhao , Jinjin Wang , Jinzhao Kang , Xiaomei Wang , Hong Yu , Cheng-Feng Du . Ni nanoparticles anchoring on vacuum treated Mo2TiC2Tx MXene for enhanced hydrogen evolution activity. Chinese Journal of Structural Chemistry, 2023, 42(10): 100159-100159. doi: 10.1016/j.cjsc.2023.100159
7. [7]
  Xinyi Hu , Riguang Zhang , Zhao Jiang . Depositing the PtNi nanoparticles on niobium oxide to enhance the activity and CO-tolerance for alkaline methanol electrooxidation. Chinese Journal of Structural Chemistry, 2023, 42(11): 100157-100157. doi: 10.1016/j.cjsc.2023.100157
8. [8]
  Anqiu LIU , Long LIN , Dezhi ZHANG , Junyu LEI , Kefeng WANG , Wei ZHANG , Junpeng ZHUANG , Haijun HAO . Synthesis, structures, and catalytic activity of aluminum and zinc complexes chelated by 2-((2,6-dimethylphenyl)amino)ethanolate. Chinese Journal of Inorganic Chemistry, 2024, 40(4): 791-798. doi: 10.11862/CJIC.20230424
9. [9]
  Bin Dong , Ning Yu , Qiu-Yue Wang , Jing-Ke Ren , Xin-Yu Zhang , Zhi-Jie Zhang , Ruo-Yao Fan , Da-Peng Liu , Yong-Ming Chai . Double active sites promoting hydrogen evolution activity and stability of CoRuOH/Co₂P by rapid hydrolysis. Chinese Chemical Letters, 2024, 35(7): 109221-. doi: 10.1016/j.cclet.2023.109221
10. [10]
  Tao Yu , Vadim A. Soloshonok , Zhekai Xiao , Hong Liu , Jiang Wang . Probing the dynamic thermodynamic resolution and biological activity of Cu(Ⅱ) and Pd(Ⅱ) complexes with Schiff base ligand derived from proline. Chinese Chemical Letters, 2024, 35(4): 108901-. doi: 10.1016/j.cclet.2023.108901
11. [11]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
12. [12]
  Guo-Ping Yin , Ya-Juan Li , Li Zhang , Ling-Gao Zeng , Xue-Mei Liu , Chang-Hua Hu . Citrinsorbicillin A, a novel homotrimeric sorbicillinoid isolated by LC-MS-guided with cytotoxic activity from the fungus Trichoderma citrinoviride HT-9. Chinese Chemical Letters, 2024, 35(8): 109035-. doi: 10.1016/j.cclet.2023.109035
13. [13]
  Simin Wei , Yaqing Yang , Junjie Li , Jialin Wang , Jinlu Tang , Ningning Wang , Zhaohui Li . The Mn/Yb/Er triple-doped CeO₂ nanozyme with enhanced oxidase-like activity for highly sensitive ratiometric detection of nitrite. Chinese Chemical Letters, 2024, 35(6): 109114-. doi: 10.1016/j.cclet.2023.109114
14. [14]
  Maitri Bhattacharjee , Rekha Boruah Smriti , R. N. Dutta Purkayastha , Waldemar Maniukiewicz , Shubhamoy Chowdhury , Debasish Maiti , Tamanna Akhtar . Synthesis, structural characterization, bio-activity, and density functional theory calculation on Cu(Ⅱ) complexes with hydrazone-based Schiff base ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(7): 1409-1422. doi: 10.11862/CJIC.20240007
15. [15]
  Yiyue Ding , Qiuxiang Zhang , Lei Zhang , Qilu Yao , Gang Feng , Zhang-Hui Lu . Exceptional activity of amino-modified rGO-immobilized PdAu nanoclusters for visible light-promoted dehydrogenation of formic acid. Chinese Chemical Letters, 2024, 35(7): 109593-. doi: 10.1016/j.cclet.2024.109593
16. [16]
  Qi Tan , Run-Zhu Fan , Wencong Yang , Ge Zou , Tao Chen , Jianying Wu , Bo Wang , Sheng Yin , Zhigang She . (+)/(−)-Mycosphatide A, a pair of highly oxidized polyketides with lipid-lowering activity from the mangrove endophytic fungus Mycosphaerella sp. SYSU-DZG01. Chinese Chemical Letters, 2024, 35(9): 109390-. doi: 10.1016/j.cclet.2023.109390
17. [17]
  Ruiying Liu , Li Zhao , Baishan Liu , Jiayuan Yu , Yujie Wang , Wanqiang Yu , Di Xin , Chaoqiong Fang , Xuchuan Jiang , Riming Hu , Hong Liu , Weijia Zhou . Modulating pollutant adsorption and peroxymonosulfate activation sites on Co3O4@N,O doped-carbon shell for boosting catalytic degradation activity. Chinese Journal of Structural Chemistry, 2024, 43(8): 100332-100332. doi: 10.1016/j.cjsc.2023.100332
18. [18]
  Maosen Xu , Pengfei Zhu , Qinghong Cai , Meichun Bu , Chenghua Zhang , Hong Wu , Youzhou He , Min Fu , Siqi Li , Xingyan Liu . In-situ fabrication of TiO₂/NH₂−MIL-125(Ti) via MOF-driven strategy to promote efficient interfacial effects for enhancing photocatalytic NO removal activity. Chinese Chemical Letters, 2024, 35(10): 109524-. doi: 10.1016/j.cclet.2024.109524

Get Citation

PDF

XML

Metrics

PDF Downloads(1)
Abstract views(157)
HTML views(4)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142